Baxter (NYSE:BAX) said today that it inked a partnership deal with Biomérieux looking to develop biomarkers to identify acute kidney injury. The partnership was announced at the International Symposium on Intensive Care and Emergency Medicine, Deerfield, Ill.-based Baxter said. Both companies said they hope to develop the biomarkers to help rapidly identify and inform treatment of acute […]
These 10 medical device companies spent the largest portion of their budgets on research and development. Here’s a look at what they produced. Each year, Medical Design & Outsourcing compiles a list of the top 100 medical device companies across the globe and ranks the companies based on annual revenue for the most recent fiscal […]
Among the world’s largest medtech companies, these 10 spent the largest portion of their budgets on research and development. So what have they produced? Every year, Medical Design & Outsourcing pulls financial regulatory filings and reaches out to major, companies in some cases to create a list of the 100 largest medical device companies in […]
Eric Bouvier took over the corner office at BG Medicine (NSDQ:BGMD) yesterday as president & CEO of the Waltham, Mass.-based diagnostics developer.
Prior to joining BG, Bouvier, 51, headed the Immunoassay business at global diagnostics company BioMérieux. He also held the role of president & CEO of BioMérieux’s U.S. subsidiary bioMerieux Inc.
Boston Scientific Corp.’s (NYSE:BSX) Promus Element drug-eluting stent for small vessels won a nod from the FDA and BSX earned a ratings upgrade from investment bank Goldman Sachs.
The Natick, Mass.-based medical device maker said FDA regulators approved its Promus everolimus-eluting coronary stent for use in vessels as small as 2.25mm in diameter. The company said it plans to immediately launch the product in the U.S.
BioMerieux Inc. expanded its worldwide recall of a test for certain bacterias’ resistance to a type of antibiotic.
The French French medical diagnostics maker’s Vitek 2 Gram Negative Susceptibility Cards designed to test bacteria for susceptibility to the antibiotic Piperacillin/Tazobactam (TZP) were found to provide inaccurate results.